0
0

To nullify modifications made by the Food and Drug Administration on January 3, 2023, to the risk evaluation and mitigation strategy under section 505-1 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355-1) for mifepristone, and for other purposes.

2/5/2024, 2:30 PM

Current Status of Bill HR 5850

Bill HR 5850 is currently in the status of Bill Introduced since September 29, 2023. Bill HR 5850 was introduced during Congress 118 and was introduced to the House on September 29, 2023.  Bill HR 5850's most recent activity was Referred to the Subcommittee on Health. as of October 6, 2023

Bipartisan Support of Bill HR 5850

Total Number of Sponsors
1
Democrat Sponsors
0
Republican Sponsors
1
Unaffiliated Sponsors
0
Total Number of Cosponsors
1
Democrat Cosponsors
0
Republican Cosponsors
1
Unaffiliated Cosponsors
0

Policy Area and Potential Impact of Bill HR 5850

Primary Policy Focus

Health

Alternate Title(s) of Bill HR 5850

To nullify modifications made by the Food and Drug Administration on January 3, 2023, to the risk evaluation and mitigation strategy under section 505-1 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355-1) for mifepristone, and for other purposes.
To nullify modifications made by the Food and Drug Administration on January 3, 2023, to the risk evaluation and mitigation strategy under section 505-1 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355-1) for mifepristone, and for other purposes.

Comments